Free Trial
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

Adaptimmune Therapeutics logo
$0.27 +0.00 (+0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.28 +0.01 (+2.16%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Key Stats

Today's Range
$0.26
$0.28
50-Day Range
$0.20
$0.32
52-Week Range
$0.20
$1.48
Volume
327,652 shs
Average Volume
1.81 million shs
Market Capitalization
$71.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.52
Consensus Rating
Hold

Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

ADAP MarketRank™: 

Adaptimmune Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 490th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Adaptimmune Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Adaptimmune Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adaptimmune Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adaptimmune Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adaptimmune Therapeutics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Adaptimmune Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.60% of the float of Adaptimmune Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adaptimmune Therapeutics has recently increased by 31.01%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Adaptimmune Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Adaptimmune Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.60% of the float of Adaptimmune Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adaptimmune Therapeutics has recently increased by 31.01%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Adaptimmune Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    8 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.

  • Read more about Adaptimmune Therapeutics' insider trading history.
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Adaptimmune Q1 2025 Earnings Preview
Adaptimmune downgraded to Hold from Buy at JonesResearch
See More Headlines

ADAP Stock Analysis - Frequently Asked Questions

Adaptimmune Therapeutics' stock was trading at $0.5387 on January 1st, 2025. Since then, ADAP stock has decreased by 49.3% and is now trading at $0.2731.
View the best growth stocks for 2025 here
.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The biotechnology company had revenue of $7.29 million for the quarter, compared to analysts' expectations of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative trailing twelve-month return on equity of 74.15%.
Read the conference call transcript
.

Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics' top institutional investors include Long Focus Capital Management LLC (9.24%), Two Seas Capital LP (7.98%), MPM Asset Management LLC (2.07%) and MPM Bioimpact LLC (1.90%). Insiders that own company stock include Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, Elliot Norry and John Lunger.
View institutional ownership trends
.

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/13/2025
Today
5/29/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADAP
Employees
490
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.52
High Stock Price Target
$3.00
Low Stock Price Target
$0.46
Potential Upside/Downside
+458.2%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.87 million
Pretax Margin
-24.73%

Debt

Sales & Book Value

Annual Sales
$179.64 million
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
1.60

Miscellaneous

Free Float
224,051,000
Market Cap
$71.13 million
Optionable
Optionable
Beta
2.86

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ADAP) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners